SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-19-069670
Filing Date
2019-12-04
Accepted
2019-12-03 20:09:56
Documents
12
Period of Report
2019-12-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm1923131-3_8k.htm   iXBRL 8-K 28430
  Complete submission text file 0001104659-19-069670.txt   203864

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tbph-20191203.xsd EX-101.SCH 3192
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20191203_lab.xml EX-101.LAB 34591
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tbph-20191203_pre.xml EX-101.PRE 22714
5 EXTRACTED XBRL INSTANCE DOCUMENT tm1923131-3_8k_htm.xml XML 3625
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 191267051
SIC: 2834 Pharmaceutical Preparations